Brief: Viking Therapeutics Q4 EPS USD -1.38 Vs. IBES Estimate USD -0.89
11/02/2026 21:17
Feb 11 (Reuters) - Viking Therapeutics Q4 income from operations USD -164.738 million vs. IBES estimate USD -107.1 million. Q4 net income USD -157.662 million vs. IBES estimate USD -101.6 million Q4 operating expenses USD 164.738 million
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry